FDA Clears RealView Imagine 3D Interactive Tools
RealView Imaging has pioneered Holography Guided Interventions by introducing the HOLOSCOPE(tm-i) - the only system that can create true 3D volumetric holograms using medical imaging data. The HOLOSCOPE(tm),-i was designed specifically to allow physicians to interact directly with hyper-realistic 3D Holograms of patients' actual anatomy. These float in free space and are easily accessible by doctors during interventional procedures. Imaging-based minimally-invasive medical procedures are one of the fastest growing areas in medicine. The system's 3D interactive visualization tools enable this functionality.
RealView Imaging Gets FDA Clearance for the HOLOSCOPE(tm),-i Holographic Systems
RealView Imaging is granted FDA Clearance in August 2021 for its groundbreaking HOLOSCOPE(tm-i) Holographic System
FDA 510(k), clearance was granted to the company for its HOLOSCOPE (tm)-i holographic device. Based on data from standard CT scans or 3D ultrasound systems, the system creates three-dimensional interactive medical Holograms that are spatially precise and accurate. The HOLOSCOPE(tm),-i medical holography system is the only one that allows physicians to interact with dynamic holograms of patients' true anatomy in 3D. This allows for direct and precise interaction, as well as the ability to view the patient's anatomy from a distance.
The HOLOSCOPE(tm),-i system was designed to meet the needs of interventionalists and clinicians. It features an "over the head" configuration that suspends above the doctor, and does not require any special eyewear, head-mounted devices, or other interaction tools. Using the company's Digital Light Shaping (tm), the HOLOSCOPE(tm);-i system creates holograms with high spatial resolution. This is a Nobel Prize-winning technology. This technological advantage is unique and allows natural 3D/4D visualization. The system can also be used for a long time without causing fatigue, nausea, or headaches.
Aviad Kaufman (Shaul Gelman) and Prof. Carmel Rotschild founded the company, along with a seed investment by Dr. Shimon Eckhouse who is the Chairman of its Board of Directors. RealView's core holographic technology has been developed and a strong IP portfolio was built (35 patents were filed, 21 were granted). The company's first installation of HOLOSCOPE(tm-i) commercial configuration was unveiled at Toronto General Hospital in 2019. This was done in the presence the President of Israel, Mr. Reuven Rivlin. Toronto General Hospital was recently named the fourth-best hospital in the world by Newsweek. It was also the first to use true Holographic Imaging during interventional cardiology procedures. RealView also conducted the first clinical study in Israel to assess the feasibility of 3D holographic imaging live in clinical settings. This study was done in collaboration with Philips Healthcare, Schneider Children's Medical Center, and other hospitals in Israel.
Kobi Richter, who was a major investor and is now a Director of the company, says RealView has developed a unique solution to address both fundamental usability requirements as well as a broad range of clinical needs in advanced imaging. RealView's extensive IP portfolio and technological maturity make it possible to impact the rapidly growing field of structural heart surgeries. These fields heavily rely on 3D imaging technology that will help the physician to see clearly and accurately in any intervention that is made in spaces not visible to his eyes.
RealView Imaging's vision for the future is to use its leadership position in Medical Holography to be a global leader in multiple clinical applications. The company's next-generation product, the HOLOSCOPE(tm),-x, projects 3D holographic pictures inside the patient's body. This makes the patient virtually transparent. This product is currently in development and will allow for precise, minimally invasive interventional procedures.
After spending most of his career in Medical Imaging Dr. Morry Blumenfeld was a Venture Partner at OurCrowd, formerly Managing Director at GE Healthcare Israel. He envisioned that holography would become a key tool in therapeutic medical procedures to support the required accuracy and minimize errors.
The company's series C financing round was increased to $15M earlier this year. Judith and Kobi Richter, Rami Ungar and OurCrowd VC were among the notable investors that participated in this round. This round included the participation of the majority of existing shareholders, including Zohar Gilon and Dr. Shimon Eckhouse, serial investors in medical technology and medical investors.
Dr. Elchanan Brackheimer is the Cath Lab Director at Schneider Children's Medical Center. He also serves as Medical Director for RealView Imaging. A hologram of the human heart in his hands, which is based on intra-procedure ultrasound and pre-operative CT, allows him to see and understand the complex 3D anatomy of each patient. He can intuitively understand the dynamic spatial and anatomical relationships between the leaflets of the cardiac valves using the holographic system. He can touch, mark and locate the area to be treated. He can use this technology to feel more confident, which could lead to shorter procedures and better results.
Shaul Gelman is the CEO and co-founder of RealView Imaging. He believes that there is a growing demand for advanced visualization solutions in Medical Imaging. This is driven by the increasing use of imaging technology to perform minimally invasive procedures. The next generation of 3D interactive visualization tools, the HOLOSCOPE(tm),-i, empowers imaging-based medical interventions. This allows clinicians to intuitively comprehend complex anatomy in an accessible and realistic way.
RealView's Chairman of Board, Dr. Shimon Eckhouse says that after years of research and development, RealView is thrilled to offer this science-fiction solution for real-world clinical practice.
RealView Imaging has received FDA clearance. They are now focusing on commercialization of the HOLOSCOPE (tm)-i system within North America. They also plan to expand their market reach into other countries in the coming year. RealView Imaging can make a significant impact on the expanding field of structural heart surgery, and other clinical areas that rely on advanced imaging for better and quicker medical care.
RealView Imaging's vision for the future is to use its leadership position in Medical Holography to make a difference worldwide. It plans to scale its proprietary technology to many clinical applications. The company's next product is the HOLOSCOPE(tm-x), which projects 3D holographic images within the patient's body (in situ), rendering the patient virtually transparent. This patent-pending product is currently in development and allows for minimally-invasive, in-body spatially-precise procedures.
RealView Imaging Closes the $10M Series C Round
RealView Imaging Ltd. raised $10M in a series C financing round back in July 2020. OurCrowd, a major hitech venture capital fund, Judith Richter and Kobi Richter were among the new investors. They are also notable investors and top physicians. This round included the participation of most of the company's shareholders, including Dr. Shimon Eckhouse and Zohar Gilon, as well as other prominent investors such Uzia Galil, Uzia Galil, and Zohar Gilon.
As part of Medinol's closing, Dr. Kobi Richter, founder and chairman, and Prof. Michael Eldar (ex-Director of the Cardiology Institute at Sheba Medical Center), joined the company’s Board of Directors.